ClinicalTrials.gg

Program

irinotecan sucrosofate

Also written as “Irinotecan liposome injection”, “PEP02” and “Irinotecan Liposome Injection”.

Its studies are mostly in Pancreatic Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Esophageal Squamous Cell Carcinoma · Cholangiocarcinoma, led by 9 companies.

Furthest: phase 3, since Jan 18, 202120 company-led studies, 2 open or runningNext primary completion: Dec 1, 2026 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group50 open or runningphase 2since Jan 18, 2021Jul 20, 2020none ahead
PharmaEngine50 open or runningphase 2since Dec 18, 2008Dec 18, 2008none ahead
Ipsen40 open or runningphase 3since Mar 9, 2017Dec 19, 2012none ahead
Cardiff Oncology10 open or runningphase 2since Feb 9, 2021Feb 9, 2021none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Sep 29, 2021Sep 29, 2021none ahead
Merrimack Pharmaceuticals10 open or runningphase 3since Dec 14, 2011Dec 14, 2011none ahead
Shanghai Runshi Pharmaceutical Technology11 open or runningphase 2since Jul 9, 2024Jul 9, 2024none ahead
SONIRE Therapeutics11 open or runningearly phase 1since Jun 5, 2025Jun 5, 2025Dec 1, 2026early phase 1 · NCT07033689
Sorrento Therapeutics10 open or runningphase 3since Jul 26, 2019Jul 26, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Dec 18, 2008.

  1. Sep 10, 2015Phase 2 study in Pancreatic NeoplasmsIpsen · NCT02551991 · 56 enrolled · United States, Australia, Spain
  2. Aug 12, 2016Phase 1 study in Solid TumorPharmaEngine · NCT02884128 · 16 enrolled
  3. Mar 9, 2017Phase 3 study in Small Cell Lung CarcinomaIpsen · NCT03088813 · 491 enrolled · United States, Australia, Belgium and more
  4. Dec 21, 2018Phase 1 study in Refractory Solid TumorsPharmaEngine · NCT03810742 · 44 enrolled · Taiwan
  5. Jul 26, 2019Sorrento Therapeutics's first study: phase 3 study in Malignant Tumor of Pancreas Metastatic to LiverNew to Sorrento TherapeuticsSorrento Therapeutics · NCT04037241
  6. Jul 20, 2020CSPC Pharmaceutical Group's first study: phase 1 study in Advanced Pancreatic CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04482257 · 48 enrolled · China
  7. Jan 18, 2021Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT04728035 · 119 enrolled · China
  8. Jan 18, 2021Phase 2 study in Small Cell Lung CarcinomaCSPC Pharmaceutical Group · NCT04727853 · 66 enrolled · China
  9. Feb 9, 2021Cardiff Oncology's first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
  10. Aug 4, 20212 phase 2 studiesCSPC Pharmaceutical Group · NCT05009953, NCT05047991
  11. Sep 29, 2021Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05086822 · 32 enrolled · China
  12. May 3, 2022Phase 1 study in Metastatic Pancreatic AdenocarcinomaIpsen · NCT05383352 · 177 enrolled · Australia, France, Germany and more
  13. Jul 9, 2024Shanghai Runshi Pharmaceutical Technology's first study: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06512428 · 138 planned · China
  14. Jun 5, 2025SONIRE Therapeutics's first study: early phase 1 study in Pancreatic NeoplasmsNew to SONIRE TherapeuticsSONIRE Therapeutics · NCT07033689 · 10 planned · United States

Ahead

  1. Dec 1, 2026Primary completion: early phase 1 study in Pancreatic NeoplasmsSONIRE Therapeutics · NCT07033689

TargetBeta

TOP1 →read by rule
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule

Other programs on TOP1

ProgramCompanyFurthest phaseStudies
TopotecanruleGlaxoSmithKlinephase 333

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07033689Pancreatic Neoplasms · United StatesEarly 1RecruitingSONIRE TherapeuticsDec 1, 202610
NCT06512428Advanced Esophageal Squamous Cell Carcinoma · China2RecruitingShanghai Runshi Pharmaceutical TechnologyJan 30, 2026138
NCT05383352Metastatic Pancreatic Adenocarcinoma · Australia, France, Germany and more1CompletedIpsenMay 27, 2024177
NCT05086822Advanced Solid Tumors · China1CompletedJiangsu HengRui MedicineAug 28, 201732
NCT05047991Pancreatic Cancer Non-resectable2UNKNOWNCSPC Pharmaceutical GroupNov 2023153
NCT05009953Cholangiocarcinoma · China2TerminatedCSPC Pharmaceutical GroupJan 16, 202317
NCT04752696Pancreatic Ductal Adenocarcinoma · United States2TerminatedCardiff OncologyDec 24, 202441
NCT04728035Advanced Breast Cancer · China1CompletedCSPC Pharmaceutical GroupJun 5, 2023119
NCT04727853Small Cell Lung Carcinoma · China2CompletedCSPC Pharmaceutical GroupApr 26, 202266
NCT04482257Advanced Pancreatic Cancer · China1UNKNOWNCSPC Pharmaceutical GroupDec 202048
NCT04037241Malignant Tumor of Pancreas Metastatic to Liver3WithdrawnSorrento TherapeuticsJan 1, 20220
NCT03810742Refractory Solid Tumors · Taiwan1CompletedPharmaEngineMay 4, 202244
NCT03088813Small Cell Lung Carcinoma · United States, Australia, Belgium and more3CompletedIpsenFeb 8, 2022491
NCT02884128Solid Tumor1CompletedPharmaEngineAug 200816
NCT02551991Pancreatic Neoplasms · United States, Australia, Spain2CompletedIpsenFeb 15, 202156
NCT01770353Triple Negative Breast Neoplasms · United States1CompletedIpsenOct 2, 201845
NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more3CompletedMerrimack PharmaceuticalsFeb 2014417
NCT00940758Colorectal Neoplasms · Taiwan1CompletedPharmaEngineMay 201218
NCT00813163Pancreatic Neoplasms · United States, Taiwan2CompletedPharmaEngineDec 201041
NCT00813072Stomach Neoplasms · Bosnia and Herzegovina, Croatia, Korea, Republic of and more2CompletedPharmaEngineJul 2010135

How it is read

Names in the registry

  • “Irinotecan liposome injection”, 5 entries
  • “PEP02”, 4 entries
  • “Irinotecan Liposome Injection”, 3 entries
  • “MM-398”, 2 entries
  • “Nanoliposomal irinotecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.